Pre‐transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors

Pre‐transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors

Abstract Background The role of pre‐hematopoietic stem cell transplantation (HSCT) cytoreduction with either induction chemotherapy (IC) or hypomethylating agents (HMAs) in treating advanced myelodysplastic syndrome (MDS) remains debatable. We aimed to evaluate pre‐HSCT strategies by comparing the e...

Full description

Bibliographic Details
Main Authors: Yu‐Qian Sun, Lan‐Ping Xu, Kai‐Yan Liu, Xiao‐Hui Zhang, Chen‐Hua Yan, Jian Jin, Xiao‐Jun Huang, Yu Wang
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Cancer Communications
Subjects:
myelodysplastic syndrome
cytoreduction
hypomethylating agent
induction chemotherapy
hematopoietic stem cell transplantation
best supportive care
Online Access:https://doi.org/10.1002/cac2.12140

Internet

https://doi.org/10.1002/cac2.12140

Similar Items